<DOC>
	<DOCNO>NCT02055274</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetics ( PK ) LY03003 follow multiple escalate intramuscular injection , compare Neupro patch evaluate safety tolerability preliminary efficacy multiple ascend dose ( MAD ) LY03003 follow intramuscular injection .</brief_summary>
	<brief_title>Pharmacokinetics Safety Study LY03003 Patients With Early-stage Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>1 . Subject Idiopathic Parkinson 's Disease define cardinal sign , Bradykinesia , plus presence least 1 follow : rest tremor , rigidity , impairment postural reflex , without know suspected cause Parkinsonism 2 . Subject Hoehn &amp; Yahr stage ≤3 3 . Subject male female age ≥18 year Screening 4 . Subject Mini Mental State Examination ( MMSE ) score ≥25 5 . Subject Unified Parkinson 's Disease Rating Scale ( UPDRS ) motor score ( Part III ) ≥10 ≤30 Screening 1 . Subject atypical Parkinson 's syndrome ( ) due drug ( e.g. , Metoclopramide , Flunarizine ) , metabolic neurogenetic disorder ( e.g. , Wilson 's Disease ) , Encephalitis , Cerebrovascular Disease , Degenerative Disease ( e.g. , progressive Supranuclear Palsy ) 2 . Subject history Pallidotomy , Thalamotomy , deep brain stimulation , fetal tissue transplant 3 . Subject dementia , active psychosis hallucination , clinically significant depression 4 . Subject lifetime history suicide attempt ( include active attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( `` Yes '' ) either Question 4 Question 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) Screening 5 . Subject history symptomatic orthostatic hypotension decrease ≥20 mmHg systolic blood pressure ( SBP ) ≥10 mmHg diastolic blood pressure change supine stand position supine position least 5 minute within 28 day prior Screening Visit , SBP le 105 mmHg study entry , report clinical sign clinically significant orthostatic hypotension within 28 day prior Screening Visit . 6 . Subject receive therapy dopamine agonist ( DA ) either concurrently do within 28 day prior Screening 7 . Subject receive therapy 1 follow drug either concurrently within 28 day prior screen : MAOB inhibitor , DA release agent , DA modulating agent , DA antagonists , neuroleptic , medication may interact DA function . 8 . Subject currently receive central nervous system active therapy ( e.g. , sedative , hypnotic , antidepressant , anxiolytic ) , unless dose stable least 28 day prior Screening Visit likely remain stable duration study . Patients take medication within 8 hour prior clinical visit 9 . Subject current diagnosis epilepsy , history seizure adult , history stroke , transient ischemic attack within 1 year prior Screening 10 . Subject history know intolerance/hypersensitivity nondopaminergic antiemetic , domperidone , ondansetron , tropisetron , glycopyrrolate 11 . Subject clinically relevant hepatic , renal cardiac dysfunction , medical condition laboratory abnormality include abnormal plasma magnesium level , would judgment investigator , interfere subject 's ability participate study 12 . Subject history significant skin hypersensitivity adhesive transdermal preparation recent unresolved contact Dermatitis ( item specific patient enrol part 2 study ) 13 . Subjects Creactive protein level 2x upper limit normal range 14 . Female subject pregnant breastfeed childbearing potential without adequate contraception . 15 . Patients positive finding drug screen test alcohol test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Parkinsons</keyword>
</DOC>